Lecturio Medical - The MEN-2 syndrome is also inherited autosomal dominantly and can further be divided into the Sipple's syndrome (2a), the Gorlin's syndrome (2b) and the FMTC-only (familial medullary thyroid carcinoma).
![Genetics of parathyroid tumours - Thakker - 2016 - Journal of Internal Medicine - Wiley Online Library Genetics of parathyroid tumours - Thakker - 2016 - Journal of Internal Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/5d3acb19-38a4-4291-9b4d-19d367bb91a1/joim12523-fig-0002-m.jpg)
Genetics of parathyroid tumours - Thakker - 2016 - Journal of Internal Medicine - Wiley Online Library
![Frontiers | Multiple Endocrine Neoplasia Type 1 (MEN1): An Update and the Significance of Early Genetic and Clinical Diagnosis | Endocrinology Frontiers | Multiple Endocrine Neoplasia Type 1 (MEN1): An Update and the Significance of Early Genetic and Clinical Diagnosis | Endocrinology](https://www.frontiersin.org/files/Articles/432573/fendo-10-00339-HTML/image_m/fendo-10-00339-t003.jpg)
Frontiers | Multiple Endocrine Neoplasia Type 1 (MEN1): An Update and the Significance of Early Genetic and Clinical Diagnosis | Endocrinology
![Current and emerging therapies for PNETs in patients with or without MEN1 | Nature Reviews Endocrinology Current and emerging therapies for PNETs in patients with or without MEN1 | Nature Reviews Endocrinology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fnrendo.2018.3/MediaObjects/41574_2018_Article_BFnrendo20183_Fig2_HTML.jpg)
Current and emerging therapies for PNETs in patients with or without MEN1 | Nature Reviews Endocrinology
![Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial - The Lancet Oncology Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/3a00553f-9ef3-4fcf-9294-eb93dd7dc34e/gr1.gif)
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial - The Lancet Oncology
![Childhood Multiple Endocrine Neoplasia (MEN) Syndromes Treatment (PDQ®)–Patient Version - National Cancer Institute Childhood Multiple Endocrine Neoplasia (MEN) Syndromes Treatment (PDQ®)–Patient Version - National Cancer Institute](https://nci-media.cancer.gov/pdq/media/images/805085.jpg)
Childhood Multiple Endocrine Neoplasia (MEN) Syndromes Treatment (PDQ®)–Patient Version - National Cancer Institute
![Frontiers | Multiple Endocrine Neoplasia Type 1 (MEN1): An Update and the Significance of Early Genetic and Clinical Diagnosis | Endocrinology Frontiers | Multiple Endocrine Neoplasia Type 1 (MEN1): An Update and the Significance of Early Genetic and Clinical Diagnosis | Endocrinology](https://www.frontiersin.org/files/Articles/432573/fendo-10-00339-HTML/image_m/fendo-10-00339-t002.jpg)
Frontiers | Multiple Endocrine Neoplasia Type 1 (MEN1): An Update and the Significance of Early Genetic and Clinical Diagnosis | Endocrinology
![MEN4 and CDKN1B mutations: the latest of the MEN syndromes in: Endocrine-Related Cancer Volume 24 Issue 10 (2017) MEN4 and CDKN1B mutations: the latest of the MEN syndromes in: Endocrine-Related Cancer Volume 24 Issue 10 (2017)](https://erc.bioscientifica.com/view/journals/erc/24/10/images/ERC-17-0243fig2.jpeg)